Replies to post #198599 on NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

I would hope that patients who crossed over are differentiated from those who initially received it. Why? Because I would have to think that by the time they've crossed over their cancer is further advanced than it would have been had they been on the vaccine in the first place. I.E. I don't expect them to do as well as those who started on the vaccine in the manner specified in the protocol. Don't get me wrong, I believe some may have had tremendous benefits from being on the vaccine, I just think on average they may not have done as well.

If it were up to me, trials would use SOC historical data for comparison and all participants would get the experimental treatment. I believe that all who sign up for trials should get whatever benefit can be seen from the treatment. In that we now have right to try established by the FDA, people who can afford it may choose the certainty of getting the drug through right to try over volunteering for a trial where one in three won't be getting the drug, and they won't know it. While at least in this trial they could cross over, my point is that the cancer is more advanced by the time they did.

Gary

[exwannabe]

Now, if the current slide indicates "over 90%" (for the first time, I believe), then this would be at least 298 patients.
Thus, an increase of at least 12 patients that have crossed between the Spring 2017 refresh, and the currently reflected data ... supposedly current through November 2018.

Well, the photo from the conference I looked at shows > 90%

Thus the control arm was at least 12% progression free in the '17 dataset, and presumably more like 15-20% as not all would have progressed and crossed in that timeframe.

Possible, yes. Question is, does that imply the control arm was doing well even before cross-over? And what does that imply?

BTW, Pyrr's "do not see it" should be fairly obvious. He is asserting the trial has already failed the inter-arm comparison and thus NWBO is spinning it as a single arm trial.